Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Tetrablock Metallopolymer Electrochromes.

Gu H, Ciganda R, Castel P, Moya S, Hernandez R, Ruiz J, Astruc D.

Angew Chem Int Ed Engl. 2018 Feb 19;57(8):2204-2208. doi: 10.1002/anie.201712945. Epub 2018 Jan 24.

PMID:
29327792
2.

Erratum: PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.

Brasó-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, Plumb DA, Zakka L, Gazinska P, Liccardi G, Meier P, Gris-Oliver A, Cheang MCU, Perdrix-Rosell A, Shafat M, Noël E, Patel N, McEachern K, Scaltriti M, Castel P, Noor F, Buus R, Mathew S, Watkins J, Serra V, Marra P, Grigoriadis A, Tutt AN.

Nat Med. 2017 Jun 6;23(6):788. doi: 10.1038/nm0617-788b. No abstract available.

PMID:
28586336
3.

[The PIG-A gene as a new biomarker of mutagenesis: proof of concept and technical specifications].

Castel P, Carcopino X, Robert S, Bonetto R, Cowen D, Orsiere T.

Med Sci (Paris). 2017 Apr;33(4):432-439. doi: 10.1051/medsci/20173304014. Epub 2017 May 12. Review. French.

PMID:
28497740
4.

Erratum: PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.

Brasó-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, Plumb DA, Zakka L, Gazinska P, Liccardi G, Meier P, Gris-Oliver A, Cheang MC, Perdrix-Rosell A, Shafat M, Noël E, Patel N, McEachern K, Scaltriti M, Castel P, Noor F, Buus R, Mathew S, Watkins J, Serra V, Marra P, Grigoriadis A, Tutt AN.

Nat Med. 2017 Apr 7;23(4):526. doi: 10.1038/nm0417-526c. No abstract available.

PMID:
28388604
5.

PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.

Toska E, Osmanbeyoglu HU, Castel P, Chan C, Hendrickson RC, Elkabets M, Dickler MN, Scaltriti M, Leslie CS, Armstrong SA, Baselga J.

Science. 2017 Mar 24;355(6331):1324-1330. doi: 10.1126/science.aah6893.

6.

The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth.

Bago R, Sommer E, Castel P, Crafter C, Bailey FP, Shpiro N, Baselga J, Cross D, Eyers PA, Alessi DR.

EMBO J. 2016 Oct 17;35(20):2263. No abstract available.

7.

PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.

Brasó-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, Plumb DA, Zakka L, Gazinska P, Liccardi G, Meier P, Gris-Oliver A, Cheang MC, Perdrix-Rosell A, Shafat M, Noël E, Patel N, McEachern K, Scaltriti M, Castel P, Noor F, Buus R, Mathew S, Watkins J, Serra V, Marra P, Grigoriadis A, Tutt AN.

Nat Med. 2016 Nov;22(11):1303-1313. doi: 10.1038/nm.4198. Epub 2016 Oct 24. Erratum in: Nat Med. 2017 Jun 6;23 (6):788. Nat Med. 2017 Apr 7;23 (4):526.

8.

Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors.

Soler A, Figueiredo AM, Castel P, Martin L, Monelli E, Angulo-Urarte A, Milà-Guasch M, Viñals F, Baselga J, Casanovas O, Graupera M.

Clin Cancer Res. 2016 Dec 1;22(23):5805-5817. Epub 2016 May 25.

9.

The emerging role of serum/glucocorticoid-regulated kinases in cancer.

Castel P, Scaltriti M.

Cell Cycle. 2017 Jan 2;16(1):5-6. doi: 10.1080/15384101.2016.1232071. Epub 2016 Sep 16. No abstract available.

10.

Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.

Le X, Antony R, Razavi P, Treacy DJ, Luo F, Ghandi M, Castel P, Scaltriti M, Baselga J, Garraway LA.

Cancer Discov. 2016 Oct;6(10):1134-1147. doi: 10.1158/2159-8290.CD-16-0305. Epub 2016 Sep 7.

11.

The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth.

Bago R, Sommer E, Castel P, Crafter C, Bailey FP, Shpiro N, Baselga J, Cross D, Eyers PA, Alessi DR.

EMBO J. 2016 Sep 1;35(17):1902-22. doi: 10.15252/embj.201693929. Epub 2016 Aug 1. Erratum in: EMBO J. 2016 Oct 17;35(20):2263.

12.

PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition.

Castel P, Ellis H, Bago R, Toska E, Razavi P, Carmona FJ, Kannan S, Verma CS, Dickler M, Chandarlapaty S, Brogi E, Alessi DR, Baselga J, Scaltriti M.

Cancer Cell. 2016 Aug 8;30(2):229-242. doi: 10.1016/j.ccell.2016.06.004. Epub 2016 Jul 21.

13.

Achieving universal health coverage in France: policy reforms and the challenge of inequalities.

Nay O, Béjean S, Benamouzig D, Bergeron H, Castel P, Ventelou B.

Lancet. 2016 May 28;387(10034):2236-49. doi: 10.1016/S0140-6736(16)00580-8. Epub 2016 May 1. Review.

14.

[Some Drops of Logic in the Fog of Depression].

Castel PH.

Rev Colomb Psiquiatr. 2016 Apr-Jun;45(2):137-44. doi: 10.1016/j.rcp.2015.10.001. Epub 2015 Nov 14. Spanish.

PMID:
27132764
15.

Somatic PIK3CA mutations as a driver of sporadic venous malformations.

Castel P, Carmona FJ, Grego-Bessa J, Berger MF, Viale A, Anderson KV, Bague S, Scaltriti M, Antonescu CR, Baselga E, Baselga J.

Sci Transl Med. 2016 Mar 30;8(332):332ra42. doi: 10.1126/scitranslmed.aaf1164.

16.

Diblock Polyelectrolytic Copolymers Containing Cationic Iron and Cobalt Sandwich Complexes: Living ROMP Synthesis and Redox Properties.

Gu H, Ciganda R, Hernandez R, Castel P, Zhao P, Ruiz J, Astruc D.

Macromol Rapid Commun. 2016 Apr;37(7):630-6. doi: 10.1002/marc.201500679. Epub 2016 Feb 3.

PMID:
26841204
17.

The tumor suppressor PTEN and the PDK1 kinase regulate formation of the columnar neural epithelium.

Grego-Bessa J, Bloomekatz J, Castel P, Omelchenko T, Baselga J, Anderson KV.

Elife. 2016 Jan 26;5:e12034. doi: 10.7554/eLife.12034.

18.

Living ROMP Synthesis and Redox Properties of Diblock Ferrocene/Cobalticenium Copolymers.

Ciganda R, Gu H, Castel P, Zhao P, Ruiz J, Hernández R, Astruc D.

Macromol Rapid Commun. 2015 Nov 23. doi: 10.1002/marc.201500566. [Epub ahead of print]

PMID:
26592969
19.

Redox-Robust Pentamethylferrocene Polymers and Supramolecular Polymers, and Controlled Self-Assembly of Pentamethylferricenium Polymer-Embedded Ag, AgI, and Au Nanoparticles.

Gu H, Ciganda R, Castel P, Vax A, Gregurec D, Irigoyen J, Moya S, Salmon L, Zhao P, Ruiz J, Hernández R, Astruc D.

Chemistry. 2015 Dec 7;21(50):18177-86. doi: 10.1002/chem.201503248. Epub 2015 Oct 23.

PMID:
26494439
20.

Miniaturized INtrinsic DISsolution Screening (MINDISS) assay for preformulation.

Alsenz J, Haenel E, Anedda A, Du Castel P, Cirelli G.

Eur J Pharm Sci. 2016 May 25;87:3-13. doi: 10.1016/j.ejps.2015.09.008. Epub 2015 Sep 7.

PMID:
26360839
21.

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.

Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, Minuesa G, Morse N, Rodón J, Ibrahim Y, Cortes J, Perez-Garcia J, Galvan P, Grueso J, Guzman M, Katzenellenbogen JA, Kharas M, Lewis JS, Dickler M, Serra V, Rosen N, Chandarlapaty S, Scaltriti M, Baselga J.

Sci Transl Med. 2015 Apr 15;7(283):283ra51. doi: 10.1126/scitranslmed.aaa4442.

22.

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.

Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, Ebbesen SH, Ainscough BJ, Ramu A, Iyer G, Shah RH, Huynh T, Mino-Kenudson M, Sgroi D, Isakoff S, Thabet A, Elamine L, Solit DB, Lowe SW, Quadt C, Peters M, Derti A, Schegel R, Huang A, Mardis ER, Berger MF, Baselga J, Scaltriti M.

Nature. 2015 Feb 12;518(7538):240-4. doi: 10.1038/nature13948. Epub 2014 Nov 17.

23.

Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment.

Castel P, Toska E, Zumsteg ZS, Carmona FJ, Elkabets M, Bosch A, Scaltriti M.

Mol Cell Oncol. 2014 Oct 29;1(3):e963447. doi: 10.4161/23723548.2014.963447. eCollection 2014 Jul-Sep. Review.

24.

Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.

Tao JJ, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, Weitsman G, Barber P, Vojnovic B, Ellis H, Morse N, Viola-Villegas NT, Bosch A, Juric D, Hazra S, Singh S, Kim P, Bergamaschi A, Maheswaran S, Ng T, Penault-Llorca F, Lewis JS, Carey LA, Perou CM, Baselga J, Scaltriti M.

Sci Signal. 2014 Mar 25;7(318):ra29. doi: 10.1126/scisignal.2005125.

25.

[Pathology seen in French "Hikikomori"].

Furuhashi T, Figueiredo C, Pionnié-Dax N, Fansten M, Vellut N, Castel PH.

Seishin Shinkeigaku Zasshi. 2012;114(10):1173-9. Review. Japanese.

PMID:
23234197
26.

On methods of access to the structure of social representations: the example of Europe.

Castel P, Morlot R, Lacassagne MF.

Span J Psychol. 2012 Nov;15(3):1222-32.

PMID:
23156927
27.

Multidisciplinarity and medical decision, impact for patients with cancer: sociological assessment of two tumour committees' organization.

Castel P, Tassy L, Lurkin A, Blay JY, Meeus P, Mignotte H, Faure C, Ranchere-Vince D, Bachelot T, Guastalla JP, Sunyach MP, Guerin N, Treilleux I, Marec-Berard P, Thiesse P, Ray-Coquard I.

Bull Cancer. 2012 Apr 1;99(4):E34-42. doi: 10.1684/bdc.2012.1559.

28.

Pragmatic evidence and textual arrangements: a case study of French clinical cancer guidelines.

Knaapen L, Cazeneuve H, Cambrosio A, Castel P, Fervers B.

Soc Sci Med. 2010 Aug;71(4):685-92. doi: 10.1016/j.socscimed.2010.05.019. Epub 2010 Jun 4.

PMID:
20646809
29.

Why don't cancer patients enter clinical trials? A review.

Castel P, Négrier S, Boissel JP; Plateforme d'Aide à la Recherche Clinique en Cancérologie de la région Rhône-Alpes.

Eur J Cancer. 2006 Aug;42(12):1744-8. Epub 2006 Jun 14. Review.

PMID:
16777404
30.

Medical practices and cancer care networks: examples in oncology.

Ray-Coquard I, Chauvin F, Lurkin A, Ducimetière F, Jacquin JP, Agostini C, Pouchard I, Meyer B, Farsi F, Castel P, Perrier L, Philip T.

Bull Cancer. 2006 Feb;93(2):E13-20. Review.

31.

[Organization and impact of the multidisciplinary committee in oncology].

Castel P, Blay JY, Meeus P, Sunyach MP, Ranchère-Vince D, Thiesse P, Bergeron C, Marec-Bérard P, Lurkin A, Ray-Coquard I.

Bull Cancer. 2004 Oct;91(10):799-804. French.

32.

[Reflections toward establishing a chronology of the "transsexual phenomenon," 1910-95].

Castel P.

Rev Bras Hist. 2001;21(41):77-111. Portuguese. No abstract available.

PMID:
19697497
33.

[THE PHARMACEUTICAL SERVICE OF MONTPELLIER HOSPITALS].

CASTEL P, DULIEU L.

Scalpel (Brux). 1963 Sep 21;116:793-800. French. No abstract available.

PMID:
14088071
34.
35.

[Research on the anthelmintic activity and toxicity of diphenyl tin oxide].

CASTEL P, GRAS G, BEAULATON S.

Rev Pathol Gen Physiol Clin. 1960 Feb;60:235-43. French. No abstract available.

PMID:
13808254
36.

[Anthelmintic possibilities of lead arsenate; preliminary note].

CASTEL P, GRAS G.

Rev Pathol Gen Physiol Clin. 1959 Mar;59(706):327-30. French. No abstract available.

PMID:
13668290
37.

[Comments on the therapeutic activity of some tin derivatives with reference to the histochemical detection of tin].

TURCHINI J, KHAU VAN KIEN L, CASTEL P, THAI TUONG.

Therapie. 1958;13(5):873-6. French. No abstract available.

PMID:
13625199
38.

[The possible anthelmintic activity of some organic derivatives of tin].

CASTEL P, HARANT H, GRAS G.

Therapie. 1958;13(5):865-72. English, French. No abstract available.

PMID:
13625198
39.

[Experimental and clinical study of the anthelmintic activity of some inorganic derivatives of tin].

CASTEL P, HARANT H, GRAS G.

Therapie. 1958;13(5):843-55. French. No abstract available.

PMID:
13625197
40.

[Elimination of Hymenolepis fraterna of the mouse & rat by n-octyl stannic dichloride & dilaurate].

HARANT H, CASTEL P, GRAS G.

Bull Soc Pathol Exot Filiales. 1957 May-Jun;50(3):427-33. French. No abstract available.

PMID:
13479760
41.

[Anthelminthic value of some mineral compounds of tin].

CASTEL P, GRAS G, HARANT H.

Montp Med. 1956 May;49(5):432-43. French. No abstract available.

PMID:
13378373
42.

[Treatment of pinworm infection by tetracycline].

Harant H, Castel P, Gras G.

Bull Soc Pathol Exot Filiales. 1954;47(6):822-5. French. No abstract available.

PMID:
14378922

Supplemental Content

Loading ...
Support Center